You are here

‘Breath Test’ Shows Promise for Diagnosing Fungal Pneumonia

Noninvasive method detects compounds produced by Aspergillus fungi

Many different microbes can cause pneumonia, and treatment may be delayed or off target if doctors cannot tell which bug is the culprit. A new approach — analyzing a patient’s breath for key chemical compounds made by the infecting microbe — may help detect invasive aspergillosis, a fungal infection that is a leading cause of mortality in patients with compromised immune systems, according to a proof-of-concept study published online in Clinical Infectious Diseases.

Currently difficult to diagnose, this type of fungal pneumonia often requires a lung biopsy for definitive identification. For debilitated patients with weakened immune systems, including organ or bone-marrow transplant recipients and patients on chemotherapy, such an invasive procedure may be challenging. A noninvasive method that can also identify the type of fungus causing pneumonia could lead to earlier and more targeted treatment in these cases, the report suggests.

Sophia Koo, MD, of Brigham and Women’s Hospital in Boston, and her colleagues wondered whether they could find a unique “chemical signature” in the breath of patients being evaluated for fungal pneumonia. In the lab, they identified several compounds, or metabolites, normally produced by Aspergillus fumigatus and other fungi that can cause pneumonia.

The researchers then analyzed breath samples from 64 patients with suspected cases of invasive aspergillosis and assessed whether it was possible to distinguish patients with this fungal pneumonia from patients who did not have the illness.

Based on the identification of fungal compounds in the breath samples, they identified patients with the fungal infection with high accuracy — 94% sensitivity and 93% specificity. In other words, the method was able to detect 94% of patients who had or likely had the disease, and misidentified as infected 7% of patients who were not infected.

No adverse events were related to the breath-collection procedure, the authors reported. It was well-tolerated, including by patients who had difficulty breathing or required supplemental oxygen.

“Identification of the underlying microbial etiology remains elusive in most patients with pneumonia, even with invasive diagnostic measures,” Koo said. “Our findings provide proof-of-concept that we can harness the detection of species-specific metabolites to identify the precise microbial cause of pneumonia, which may guide appropriate treatment of these infections.”

More research will be needed to validate the findings and refine the approach before it can be considered for clinical use, the authors noted. If supported by future research, the method also may have applications in other kinds of pneumonia.

“We can likely also use this volatile metabolite-profiling approach to identify other, more common causes of pneumonia,” Koo said.

Source: IDSA; October 23, 2014.

Recent Headlines

Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over Half of Patients Had Reduced Pain Levels of 30% or More
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications